Evidence map›Paper›PMID 38048277›Full record

ArticleACS infectious diseases2024

A Flexible, Quantitative Plasmonic-Fluor Lateral Flow Assay for the Rapid Detection of

Abraham J Qavi, Qisheng Jiang, M Javad Aman, Hong Vu, Larry Zetlin, John M Dye, Jeffrey W Froude, Daisy W Leung, Frederick Holtsberg, Scott L Crick and 1 more

Open access · hybridAbstract read
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Abraham J QaviDepartment of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, California 92697, United States.ORCID 0000-0002-9349-2600
Qisheng JiangAuragent Bioscience, St. Louis, Missouri 63108, United States.
M Javad AmanIntegrated Biotherapeutics, Rockville, Maryland 20850, United States.
Hong VuIntegrated Biotherapeutics, Rockville, Maryland 20850, United States.
Larry ZetlinMapp Biopharmaceutical, Inc., San Diego, California 92121, United States.
John M DyeUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, United States.
Jeffrey W FroudeUnited States Army Nuclear and Countering Weapons of Mass Destruction Agency, Fort Belvoir, Virginia 22060, United States.
Daisy W LeungDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0002-7189-9557
Frederick HoltsbergIntegrated Biotherapeutics, Rockville, Maryland 20850, United States.
Scott L CrickAuragent Bioscience, St. Louis, Missouri 63108, United States.
Gaya K AmarasingheDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, United States.ORCID 0000-0002-0418-9707
Integrated BioTherapeutics (United States) · USWashington University in St. Louis · USDefense Threat Reduction Agency · USMapp Biopharmaceutical (United States) · USUnited States Army Medical Research Institute of Infectious Diseases · USUniversity of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI ROBERT A DAVEY · 2016 to 2026
$30.2M
Development and characterization of engineered therapeutic antibodies against SARS-CoV-2R01AI161374 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2021 to 2023
$2.7M
Multi-platform High Throughput Screens for Filoviral Replication InhibitorsR01AI123926 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2016 to 2018
$2.1M
Development of Optofluidic Resonators for Filoviral DetectionK08EB033409 · NIBIB · WASHINGTON UNIVERSITY · PI QAVI, ABRAHAM JALEEL · 2022 to 2025
$759k
NCI NIH HHS P30 CA062203NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI123926NIAID NIH HHS R01 AI161374NIBIB NIH HHS K08 EB033409
6 · The paper itself

Abstract

Filoviruses comprise a family of single-stranded, negative-sense RNA viruses with a significant impact on human health. Given the risk for disease outbreaks, as highlighted by the recent outbreaks across Africa, there is an unmet need for flexible diagnostic technologies that can be deployed in resource-limited settings. Herein, we highlight the use of plasmonic-fluor lateral flow assays (PF-LFA) for the rapid, quantitative detection of an Ebolavirus-secreted glycoprotein, a marker for infection. Plasmonic fluors are a class of ultrabright reporter molecules that combine engineered nanorods with conventional fluorophores, resulting in improved analytical sensitivity. We have developed a PF-LFA for

Indexed as

EbolavirusHemorrhagic Fever, EbolaAnimalsDisease OutbreaksGlycoproteinsGlycoproteinsdiagnosticsFiloviruseslateral flow assayplasmonics

Identifiers

PMID38048277
PMCPMC10788868
OpenAlexW4389306640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.